Aytu Biopharma (AYTU) Change in Accured Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has reported Change in Accured Expenses for 17 consecutive years, with -$5.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 466.27% year-over-year to -$5.9 million in Q1 2026; TTM through Mar 2026 was -$7.1 million, a 291.06% decrease from a year earlier, with the FY2025 full-year figure at $886000.0, up 109.67% from the prior year.
• Change in Accured Expenses was -$5.9 million for Q1 2026 at Aytu Biopharma, down from $3.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $8.0 million in Q1 2023 and troughed at -$14.5 million in Q2 2022.
• A 5-year average of -$1.3 million and a median of -$1.6 million in 2025 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 574.67% in 2022 and surged 879.88% in 2025, its largest moves.
• Over 5 years, Change in Accured Expenses stood at $2.5 million in 2022, then plunged by 48.52% to $1.3 million in 2023, then jumped by 474.23% to $7.3 million in 2024, then sank by 52.72% to $3.5 million in 2025, then slumped by 270.31% to -$5.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.9 million (Q1 2026), $3.5 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.